Cumberland Pharmaceuticals Inc. declared a special cash dividend of $1.50 per share, payable on or about July 31, 2026, to shareholders of record as of July 23, 2026. This decision follows a strategic transaction with Apotex Health Corp. that resulted in $100 million in cash at closing, with an additional $11 million expected. The Board also authorized a $5 million open-market share repurchase program. Cumberland Pharmaceuticals Inc. is a pharmaceutical company that develops and commercializes FDA-approved products.

On July 1, 2026, Cumberland Pharmaceuticals completed the sale of its FDA-approved products—including Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ—to Nuvo Pharmaceuticals (Ireland) DAC and affiliates of Apotex Inc. for $100 million in cash. The company retained its ifetroban product candidates and Cumberland Emerging Technologies, Inc. On June 29, 2026, the company used funds to repay approximately $5.3 million in outstanding obligations under a Revolving Credit Loan Agreement with Pinnacle Bank. Additionally, Chris T. Bitterman (VP Sales & Marketing) and James L. Herman (VP Trade & Distribution and Corporate Compliance Officer) will resign effective July 31, 2026, to join an Apotex affiliate. Cumberland Pharmaceuticals is a pharmaceutical company that develops and commercializes specialty medications.

Cumberland Pharmaceuticals Inc. shareholders approved a strategic transaction to integrate its commercial products with the U.S. branded business of an Apotex Inc. affiliate, as outlined in an Asset Purchase Agreement dated April 22, 2026. The proposal received 99.84% approval from votes in favor, with 10,492,455 votes in favor out of 10,509,626 present. Cumberland Pharmaceuticals Inc. is a pharmaceutical company that manages FDA-approved commercial products.